Project description DEENESFRITPL Improving the treatment of acute heart failure Chronic heart failure is an important medical challenge that may lead to acute heart failure (AHF), the most common cause of hospitalisation for individuals over the age of 65. Standard treatment of AHF involves the administration of diuretics to facilitate fluid decongestion. However, a significant proportion of AHF patients have developed diuretic resistance. With the numbers of AHF cases projected to increase due to the ageing population, the EU-funded Doraya project has developed an innovative catheter device as an alternative to diuretic treatment, offering an optimal solution for restoring organ function. Show the project objective Hide the project objective Objective Acute Heart Failure (AHF) is a sudden worsening of the signs and symptoms of chronic heart failure, which typically includesdifficulty in breathing, leg or feet swelling and fatigue. HF is a growing global problem, affecting millions of people around theworld (present in 1%-12% in Europe and the United States. The lifetime risk of developing the disease ranging in between20%-33%). AHF is the most common cause of hospitalization for patients older than 65 years of age. Over the last 3decades, the hospitalization rates for patients with AHF has tripled and is expected to increase. An ageing population willincrease the prevalence of AHF, which in turn will lead to significant monetary expenses. Fluid decongestion is the keytreatment of AHF, where 90% of patients are treated with diuretics. However, 30%-40% of patients are resistant to diuretics.The DorayaTM is the first device to directly create an optimal hemodynamic environment, enabling diuretic efficiency torelieve congestion and restore organ function. The DorayaTM catheter regulates vascular hemodynamics in AHF patients,including those who have developed diuretic resistance. Chronic Heart Failure market is expected to increase from €2.64bnin 2015 to €8.78bn in 2025, which represents a 12.9% of CAGR. Since, AHF market accounts for 75% of the total ChronicHeart Failure market, the total available global market by 2025 is expected to reach €6.59bn. With 30% of patients resistantto diuretics, this represents a huge unmet market that Doraya can service. Fields of science social sciencessociologydemographymortalitymedical and health sciencesclinical medicinecardiology Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator REVAMP MEDICAL LTD Net EU contribution € 50 000,00 Address 7 GIBOREY ISRAEL ST 4250407 NETANIA Israel See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
